Biscard

Characteristics

Selective бета_|1|-адреноблокато��. When used in therapeutic doses does not have internal simpatomimeticescoy activity and clinically significant мембраностабилизирую щими properties.

Pharmacokinetics

After receiving the drug inside bisoprolol well absorbed from the digestive tract. Bioavailability of 80-90% and is not dependent on the meals. S_max in whey is 2-4 h after administration of the interior. Linking blood plasma proteins is about 30%. The minimum is metabolizmu first participation "in the liver (20%) .T_1/2 9-12 p.m. Patients who are older this period several times, in particular with regard to the often observed in the group of patients impaired Pocek.permannaya bisoprolola concentration in the serum is for a period of five days (to the drug once a day). Bisoprolol extracted through kidney : About 50% of the dose from urine, unedited, and the remainder in the form of inactive metabolites. Less than 20% of the dose appears to Kalom.bisoprolol not metabolised in the liver, with the participation of zitohroma R450.

Indications

Arterial hypertension (when alone or with other hypotensive drugs); Drinking.

Pregnancy and lactation

Contraindicated with the use of pregnancy and breast-feeding because of the lack of reliable clinical evidence of the safety of Preparata.v pilot studies had revealed violations of reproductive function and changes in the offspring.

Contraindications

Гиперчувствительност ь bisoprololu to, or any other component of the preparation, cardiogenny shock, cardiac failure, cardiac blockade ( предсердно-желудочко��ая blockade II or III level), aetiology (HR least 45 u. / min), arterial gipotenzia (Sad below 90 mm Hg. Art.) , bronchial asthma and other obstructive respiratory disease, severe violations of peripheral blood circulation, admission MAO inhibitors, psoriasis (including family history), feohromotsytoma, pregnancy, breast-feeding.

Specific guidance

Patients with feohromotsytoma Bisokard may be nominated only after receiving alfa-adrenoblokatorov because there is a risk of arterial paradoxical Gipertenzii.v individual cases, the application бета-адреноблокаторо�� can cause development or deterioration of the current psoriasis or cause psoriazopodobnykh Vsapani.na a reception �ета-адреноблокаторов �destroy a heavier form of increased reaction Cuvstvenosti.pri treatment b ета-адреноблокаторам�� individual cases are hair loss, hearing problems or noise in the winter, the increase in body mass index, the change in mood, short-term memory loss, allergic Rinit.v case a planned surgical treatment, the abolition of a drug for 48 h prior to the general anesthesia. In other cases before the surgery should inform the license for admission Бисокарда.Клинически�� data on the efficacy and safety of Bisokarda children Otsuttuyut.issledovania conducted on laboratory animals have not identified cytotoxic, mutagenic or carcinogenic properties Preparata.sleduet caution in the management of transport, or in the performance of work requiring high Vnimania.vopros the possibility Occupation potentially hazardous activities that require increased attention and psychomotor speed reactions to be addressed only after a case-by-case evaluation of the patient's response to medication (especially at the beginning of treatment).

Patient interaction

Increases concentration of lidocaine plasma. Sulfasalazin increases the concentration Bisokarda plasma. Gipotenzivny effect NPVS weaken, as a result of delay sodium and blockades synthesis NG Pockami.pri simultaneous application Bisokard may exacerbate the effects antigipertenziveh Preparatov.pri simultaneous application Bisokarda and rezerpina, alfa-metildopa, clonidine or guanfazina possible sharp decline Css.pri simultaneous application Bisokarda and clonidine, naperstanki drugs, and guanfazina possible violations Provodimosti.pri simultaneous application Bisokarda and simpatomimetikov (incl. contained in the cough preparations, drops for the nose and eye drops), the bisoprolola Snijatsa.pri can simultaneously use nifedipin and other blockers calcium channel digidropiridina derivatives may increase the gipotenzivne Bisokarda.pri simultaneous application Bisokarda and verapamila or diltiazema and other medical complications may fall AD, the decline curves, and the development of arrhythmias, and / or heart failure (should not / at impose blockers calcium channels and antiaritmicescie drugs in the face of Bisocardom therapy). If you are applying Bisokarda clonidine, and the last can be cancelled only in the event that if a few days earlier was completed reception Bisokarda because of the potential of excessive rise Ad.pri simultaneous admission ergotamine derivatives (including ergotaminsoderjath from migraines) and Bisokarda may increase symptoms of peripheral Krovotreatmenia.pri simultaneous application Bisokarda and insulin or oral drugs gipoglikemicakih symptoms gipoglikemii disguised or relaxes (requires regular monitoring the level of glucose in the blood plasma).

Precautions

Caution must be exercised in the treatment of diabetes mellitus with significant fluctuations of glucose in the blood, it gipoglikemii symptoms can be masked, in treating patients follow a strict diet in the treatment of patients with metabolic azidozom, patients with severe reaction heightened sensitivity disorder, in desencibiliziruta therapy, and AV blockade I extent, in angiospasticescoy strokes (strokes Prinzmetala). If the dose of the drug had been omitted, to be taken as soon Bystree.esli to receive drug is 6700 or less, missing dose miss. Do not double dose Preparata.terapiu drug should be under regular medical supervision. The preparation to gradually abolish slowly reducing dose (this is particularly important in patients with ischemic heart disease).

Storage conditions

List B. In a dry, the dark place at a temperature of no higher than 25 ° C

Shelf life

3 years

The registration

(OL)

Directory → Organotropona funds → Cardiovascular funds → Beta-adrenoblokatora → Biscard